Fatemehsadat Amiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Fatemehsadat Amiri has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Mohammadreza Vafa
Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
4 shared publications - Farzad Shidfar
Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
3 shared publications A. Salehpour
Department of Nutrition, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication- Agha Fatemeh Hosseini
Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
1 shared publication Ali Akbar Saboor-Yaraghi
Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetic, Tehran University of Medical Sciences, Tehran, Iran
1 shared publicationAmir-Hassan Zarnani
1 shared publication
Latest Publications
- 1 April 2017
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 41 (2) , 211-216
Does Resveratrol Improve Insulin Signalling in HepG2 Cells?
- 1 April 2017
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 41 (2) , 211-216
Does Resveratrol Improve Insulin Signalling in HepG2 Cells?
- 1 August 2015
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 39 (4) , 302-307
Glycemic Control, Self-Efficacy and Fear of Hypoglycemia Among Iranian Children with Type 1 Diabetes
- 1 August 2015
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 39 (4) , 302-307
Glycemic Control, Self-Efficacy and Fear of Hypoglycemia Among Iranian Children with Type 1 Diabetes
- 1 October 2013
- Published by Elsevier in European Journal of Pharmacology
- Vol. 718 (1-3) , 34-40
Synergistic anti-proliferative effect of resveratrol and etoposide on human hepatocellular and colon cancer cell lines
- 1 October 2013
- Published by Elsevier in European Journal of Pharmacology
- Vol. 718 (1-3) , 34-40
Synergistic anti-proliferative effect of resveratrol and etoposide on human hepatocellular and colon cancer cell lines
- 27 July 2013
- Published by Wiley in Diabetic Medicine
- Vol. 30 (12) , 1477-1481
Does vitamin D3 supplementation improve glucose homeostasis in overweight or obese women? A double‐blind, randomized, placebo‐controlled clinical trial
Aims: Vitamin D deficiency is considered as a risk factor in cardiometabolic disorders, including cardiovascular diseases, hypertension and Type 2 diabetes mellitus. We have investigated the effect of vitamin D3 supplementation on glucose homeostasis in healthy overweight and obese women.Methods: In a double‐blind randomized placebo‐controlled clinical trial, 77 healthy overweight or obese women (mean age 38 ± 8 years; BMI 29.9 ± 4.2 kg/m2) were randomly assigned to the vitamin D3 group (25 μg/day as cholecalciferol tablets) or the placebo group. Selected anthropometric indices, glucose, insulin, HbA1c and homeostasis model assessment of insulin resistance at baseline and after 12 weeks were measured. Dietary intakes using 24‐h food recall and food frequency questionnaires were assessed. Physical activity was assessed by the International Physical Activity Questionnaire. Adjusted mean differences were calculated using analysis of covariance. Correlation coefficients were calculated by Pearson's analysis.Results: Mean fasting blood glucose concentrations declined in the vitamin D3 and placebo groups (–0.28 ± 0.4 vs. –0.65 ± 0.4 mmol/l, P < 0.001) and the mean percentage of HbA1c was decreased (–13 ± 18 vs. –19 ± 17 mmol/l, P = 0.06) in both groups, respectively. Mean 25‐hydroxyvitamin D concentrations increased in the vitamin D3 and placebo groups (38.2 ± 32 vs. 4.6 ± 14 nmol/l, P < 0.001), respectively. There was a significant correlation between HbA1c and 25‐hydroxyvitamin D concentrations (r = –0.271; P = 0.018).Conclusions: The results indicate that the vitamin D3 supplement of 25 μg/day had no beneficial effect on glycaemic indices in healthy overweight or obese women.
- 27 July 2013
- Published by Wiley in Diabetic Medicine
- Vol. 30 (12) , 1477-1481
Does vitamin D3 supplementation improve glucose homeostasis in overweight or obese women? A double‐blind, randomized, placebo‐controlled clinical trial
Aims: Vitamin D deficiency is considered as a risk factor in cardiometabolic disorders, including cardiovascular diseases, hypertension and Type 2 diabetes mellitus. We have investigated the effect of vitamin D3 supplementation on glucose homeostasis in healthy overweight and obese women.Methods: In a double‐blind randomized placebo‐controlled clinical trial, 77 healthy overweight or obese women (mean age 38 ± 8 years; BMI 29.9 ± 4.2 kg/m2) were randomly assigned to the vitamin D3 group (25 μg/day as cholecalciferol tablets) or the placebo group. Selected anthropometric indices, glucose, insulin, HbA1c and homeostasis model assessment of insulin resistance at baseline and after 12 weeks were measured. Dietary intakes using 24‐h food recall and food frequency questionnaires were assessed. Physical activity was assessed by the International Physical Activity Questionnaire. Adjusted mean differences were calculated using analysis of covariance. Correlation coefficients were calculated by Pearson's analysis.Results: Mean fasting blood glucose concentrations declined in the vitamin D3 and placebo groups (–0.28 ± 0.4 vs. –0.65 ± 0.4 mmol/l, P < 0.001) and the mean percentage of HbA1c was decreased (–13 ± 18 vs. –19 ± 17 mmol/l, P = 0.06) in both groups, respectively. Mean 25‐hydroxyvitamin D concentrations increased in the vitamin D3 and placebo groups (38.2 ± 32 vs. 4.6 ± 14 nmol/l, P < 0.001), respectively. There was a significant correlation between HbA1c and 25‐hydroxyvitamin D concentrations (r = –0.271; P = 0.018).Conclusions: The results indicate that the vitamin D3 supplement of 25 μg/day had no beneficial effect on glycaemic indices in healthy overweight or obese women.
- 1 August 2012
- Vol. 3 (8) , 531-6
Effects of cinnamon consumption on glycemic status, lipid profile and body composition in type 2 diabetic patients.
Type 2 diabetes is the most common metabolic disorder worldwide. Traditional herbs and spices can be used to control blood glucose concentrations. The objective of this study was to evaluate the effects of the daily intake of three grams cinnamon over eight weeks on glycemic status, lipid profiles and body composition in type 2 diabetic patients. A double blind, randomized, placebo controlled clinical trial was conducted on 44 patients with type 2 diabetes. Participants were randomly assigned to take either a three g/day cinnamon supplement (n=22) or a placebo (n=22) for eight weeks. Weight, height, body fat mass and systolic and diastolic blood pressure were measured at baseline and after intervention. The fasting blood glucose, insulin, HbA1c, total cholesterol, LDL C, HDL C, Apo lipoprotein A I and B were measured at baseline and endpoint. From 44 subjects participated in this study 37 completed the study. There were no significant differences in baseline characteristics, dietary intake and physical activity between groups. In the treatment group, the levels of fasting blood glucose, HbA1c, triglyceride, weight, BMI and body fat mass decreased significantly compared to baseline, but not in placebo group. No significant differences were observed in glycemic status indicators, lipid profile and anthropometric indicators between the groups at the end of intervention. These data suggest that cinnamon may have a moderate effect in improving glycemic status indicators.
- 1 August 2012
- Vol. 3 (8) , 531-6
Effects of cinnamon consumption on glycemic status, lipid profile and body composition in type 2 diabetic patients.
Type 2 diabetes is the most common metabolic disorder worldwide. Traditional herbs and spices can be used to control blood glucose concentrations. The objective of this study was to evaluate the effects of the daily intake of three grams cinnamon over eight weeks on glycemic status, lipid profiles and body composition in type 2 diabetic patients. A double blind, randomized, placebo controlled clinical trial was conducted on 44 patients with type 2 diabetes. Participants were randomly assigned to take either a three g/day cinnamon supplement (n=22) or a placebo (n=22) for eight weeks. Weight, height, body fat mass and systolic and diastolic blood pressure were measured at baseline and after intervention. The fasting blood glucose, insulin, HbA1c, total cholesterol, LDL C, HDL C, Apo lipoprotein A I and B were measured at baseline and endpoint. From 44 subjects participated in this study 37 completed the study. There were no significant differences in baseline characteristics, dietary intake and physical activity between groups. In the treatment group, the levels of fasting blood glucose, HbA1c, triglyceride, weight, BMI and body fat mass decreased significantly compared to baseline, but not in placebo group. No significant differences were observed in glycemic status indicators, lipid profile and anthropometric indicators between the groups at the end of intervention. These data suggest that cinnamon may have a moderate effect in improving glycemic status indicators.